This study is for individuals ages 18-65, who have active opioid use disorder and are interested in receiving long-acting injectable naltrexone injections (Vivitrol®).
This study will test if adding an additional medication called buprenorphine-naloxone will help people stay on long-acting naltrexone injections.
Participants starting treatment with Vivitrol® will be randomly assigned to receive additional buprenorphine or placebo tablets. Random means by chance, it’s like flipping a coin.
You will be monitored over 24 weeks (6 months).
This includes:
- Receiving injectable naltrexone (Vivitrol®) every 4 weeks.
- Weekly sessions with a medical clinician and research (medical check-in, vital sign check, and urine drug screening).
Compensation will be provided after each study visit.
Please call or text 240-739-0626 for more information.
